Bortezomib-based Regimens and Plasma Cell Leukemia

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation

Plasma cell leukemia (PCL) is a rare disease that represents approximately 4% of plasma cell malignant disorders. PCL consists of two variants: primary PCL presents in patients with no previous history of multiple myeloma, while secondary PCL consists of a leukemic transformation in a previously recognized multiple myeloma. Primary PCL is an extremely resistant, rapidly progressive, fatal disea...

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report

BACKGROUND Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents. CASE PRESENTATION A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We emplo...

Plasma cell leukemia

Paciente do gênero feminino, 74 anos, procurou o hospital com quadro de insuficiência renal e lesões líticas em coluna vertebral, sendo feito diagnóstico de mieloma múltiplo IgG kappa. Na ocasião, observaram-se monossomia do cromossomo 13 e rearranjo do IgH no FISH. A paciente foi submetida a cinco ciclos de VMP (bortezomibe, melfalan e prednisona) com resposta com pleta; foi iniciada a manuten...

Plasma cell leukemia.

Secondary plasma cell leukemia.

Plasma cell leukemia (PCL) is a rare disease and is the least common variant of multiple myeloma accounting for 2-3% of all plasma cell dyscrasias. We report a patient who was diagnosed with multiple myeloma, 12 months earlier; he was treated with VBCMP, VCMP regime, and after 12 months he presented of high grade fever, weakness, palpitations, loss of appetite, bone pains, dyspnea. Initial eval...